Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:2/16/2010

l also receive, on a blinded basis, either intravenous placebo or intravenous REOLYSIN. All dosing takes place in the first five days of each cycle with all patients receiving standard intravenous doses of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN at a dose of 3x1010 TCID50. Patients may continue to receive the trial combination therapy for up to eight, 21-day cycles and, thereafter, blinded placebo or blinded REOLYSIN until the patient has progressive disease or meets other criteria for removal from the trial. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium.

The primary endpoint for the trial is overall survival (OS); secondary endpoints include progression free survival (PFS), objective response rate (complete response (CR) + partial response (PR)) and duration of response, and safety and tolerability of REOLYSIN when administered in combination with paclitaxel and carboplatin. The first stage of the trial is designed to enroll 80 patients. The second stage is adaptive, and is designed to enroll between 100 and 400 patients with the most probable statistical enrolment being 195 patients in this stage. This adaptive trial design allows frequent data evaluation to determine if the probability of reaching a statistically significant endpoint has been achieved.

The decision to pursue a Phase 3 trial in head and neck cancers was predicated on positive results seen in the Company's U.K. Phase 1 and Phase 2 combination REOLYSIN and paclitaxel/carboplatin clinical trials, as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Updated results from the U.K. Phase 1/2 trial reported in November 2009 demonstrated an overall response rate (PR and CR) of 42% and a total clinical ben
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Shimadzu Scientific ... Chromatograph (2D-LC), which offers a powerful separation ... The system provides a new level of ... is beneficial to scientists analyzing pharmaceutical impurities, ... products. , Comprehensive 2D-LC combines two independent ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., ... eClinical Solutions, today announced three of its experts are ... for Clinical Data Management to be held September 28 ... . The Company also announced the innovative ... overall quality in clinical trials acquired earlier this year, ...
(Date:9/17/2014)... Hussey Copper , a leader in ... copper, announces Gilmour Academy Ice Arena,s conversion of more ... solid touch surface to help protect against bacteria.  MD-Cu ... that kills greater than 99.9% of MRSA, E-coli and ... , Innovative Gilmour Academy ...
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... , AquaPure Genomic DNA Isolation ... range: 210 g DNA, , Method ... 1. Dissect tissue sample quickly and freeze in liquid nitrogen. Store , ... , keep tissue on ice at all times including when tissue ...
... Lisa Starr and William D. Huse , Ixsys, ... San Diego, California 92121 , , ... M13 vectors have been used extensively for subcloning mainly because the , ... DNA is a superior starting material for sequencing and in vitro ...
... and Ian Spendlove, Cancer Research,Campaign Academic Unit, Nottingham City Hospital, Hucknall Road,Nottingham NG5 1PB, ... Introduction , ... method of DNA vaccine delivery, and has been ... protective immunity in animal models to both infectious diseases and cancer , ...
Cached Biology Technology:Genomic DNA Isolation From 510 mg Marine Invertebrate Tissue 2Electrotransformation of E. coli With M13 DNA 2Electrotransformation of E. coli With M13 DNA 3Electrotransformation of E. coli With M13 DNA 4Electrotransformation of E. coli With M13 DNA 5Electrotransformation of E. coli With M13 DNA 6Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 2Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 3Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 4Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 5Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 6Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 7Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 8
(Date:9/17/2014)... Washington, USA -- "Nature has developed, very cleverly, some ... desire in optical design," said Joseph Shaw, director of ... we explore surfaces and structures at the nanoscale, we,ll ... in San Diego in August during a conference called ... Shaw and Rongguang Liang of the University of Arizona ...
(Date:9/17/2014)... Spanish researchers have obtained the first partial genome sequence ... pig found at the site of the Montsoriu Castle ... pig is closely related to today,s Iberian pig. Researchers ... with modern Iberian pigs. , The study, published in ... of pig species, and particularly on that of the ...
(Date:9/17/2014)... team of researchers working on a Carnegie expedition in ... rates have plummeted 40% since the mid-1970s. The scientists ... role in this perilous slowdown. , In a ... reefs, the team compared current measurements of the growth ... with similar measurements taken more than 30 years ago. ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Iberian pig genome remains unchanged after 5 centuries 2Coral growth rate plummets in 30-year comparison 2
... Veterinary Medicine have identified a gene in Labrador retriever dogs ... intense hunting or retrieving exercise, activities these dogs are trained ... hind limbs. In most cases, their legs get wobbly ... dogs may die. Labradors are the most common dog ...
... mean solar or wind power. In fact, the alternative ... engineering professor James Dumesic look a lot like the ... That,s because the new fuels are identical at the ... is where they come from. Funded by the ...
... have succeeded in tracing intricate biochemical networks involving a ... in specific tissues at particular moments in development. ... Krainer, Ph.D., both professors at CSHL and heads of ... call RNA splicing. Splicing is a key step ...
Cached Biology News:U of M researchers identify gene linked to common ailment in labrador retrievers 2New process derives 'green gasoline' from plant sugars 2CSHL team traces extensive networks regulating alternative RNA splicing 2CSHL team traces extensive networks regulating alternative RNA splicing 3CSHL team traces extensive networks regulating alternative RNA splicing 4
XEDAR Antibody...
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: